Results 241 to 250 of about 4,478,342 (326)

Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER‐Medicare 2007–2015

Obesity, EarlyView.
ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez, Omer Abdelgadir, Yuanyi Zhang, Jesús Gibran Hernández‐Pérez, Maryam R. Hussain, Mohanad Albayyaa, Rasmi Nair, Yong‐Fang Kuo, Jaime P. Almandoz, Lindsay G. Cowell, Sarah E. Messiah   +10 more
wiley   +1 more source

Fast Quantitative Evaluation of the Amelioration Effect in MASLD During Semaglutide Treatment Using Ultrasound‐Derived Fat Fraction and Fat‐to‐Muscle Ratio

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang, Ruping Yang, Ying Wang, Xiu‐Yun Lu, Li Wei, Rui Cheng, Juan Cheng, Yijie Qiu, Shiwen Wang, Bo Li, Yi Dong   +10 more
wiley   +1 more source

Elevated cardiometabolic index is associated with an increased risk of cardiovascular and all-cause mortality in patients undergoing dialysis: a retrospective cohort study. [PDF]

BMC Nephrol
Li Z, Chen H, Hong B, Cai M, Wan J.
europepmc   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Association between cardiometabolic index and overactive bladder in U.S. adults: findings from NHANES [2017-2020]. [PDF]

Transl Androl Urol
Chen J, Zhang W, Zhang Z, Tang Q, Liu B, Nie Z, Gao X, Qiu J, Xu G.   +8 more
europepmc   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source

Modified cardiometabolic index outperforms conventional indices in discriminating relative muscle loss: a cross-sectional analysis of NHANES 2011-2018. [PDF]

Eur J Med Res
Yang Y, Yuan Y, Zhang Z, Lu H, Gao K, Zhang Y.   +5 more
europepmc   +1 more source

Single‐nucleotide polymorphisms in coronary artery disease: Biological complexity, risk architecture, and implications for precision prevention

Precision Medical Sciences, EarlyView.
This graphical summary highlights the clinical application of single‐nucleotide polymorphisms‐based risk stratification in coronary artery disease. By integrating polygenic risk with clinical assessment, imaging, and preventive strategies, genetic information enables earlier risk identification, optimized screening, and personalized lifestyle and ...
Li Dai, Mosi Chen, Jun Hu, Lei Huang, Ye Yang, Chang Chen, Ying Zhuang, Yan Pan, Bingjun Qian   +8 more
wiley   +1 more source

Association between cardiometabolic index and stage progression in cardiovascular-kidney-metabolic syndrome: insights from a Chinese population-based cohort study. [PDF]

Eur J Med Res
Lyu SQ, Chen Y, Yang YM, Wang J, Wu S, Zheng LH.   +5 more
europepmc   +1 more source

Non‐Cancer Causes of Death in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Analysis

The Prostate, EarlyView.
ABSTRACT Background As overall survival improves in metastatic hormone‐sensitive prostate cancer (mHSPC), non‐cancer causes of death are increasingly relevant. Methods We conducted a real‐world multicenter study of patients diagnosed with mHSPC treated with ADT alone or in combination. Causes of death before progression to castration‐resistant prostate
Marta Garcia de Herreros, Clara Rodrigo, Laura Ferrer‐Mileo, Laia Fernández‐Mañas, Joel Mases, Nely Diaz, Antoni Vilaseca, Mariana Altamirano, Roser Gibanel, Maria José Ribal, Natalia Jimenez, Oscar Reig, Mariona Figols, Miguel Ángel Climent, Albert Font, Begoña Mellado   +15 more
wiley   +1 more source